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Background: Few estimates of health care costs related to chronic obstructive pulmonary 
disease (COPD) are available regarding commercially insured patients in the United States. 
The aims of this retrospective observational analysis of administrative data were to describe and 
compare health care resource use and costs related to COPD in the United States for patients 
with commercial insurance or Medicare Advantage with Part D benefits, and to assess cost 
trends over time.
Methods: Patient-level and visit-level health care costs in the calendar years 2006, 2007, 
2008, and 2009 were assessed for patients with evidence of COPD. Generalized linear models 
adjusting for sex, age category, and geographic region were used to investigate cost trends over 
time for patients with Medicare or commercial insurance.
Results: Medical costs, which ranged from an annual mean of US$2382 (Medicare 2007) 
to US$3339 (commercial 2009) per patient, comprised the majority of total costs in all years 
for patients with either type of insurance. COPD-related costs were less for Medicare than 
  commercial cohorts. In the multivariate analysis, total costs increased by approximately 6% per 
year for commercial insurance patients (cost ratio 1.06; 95% confidence interval [CI] 1.04–1.07; 
P , 0.001) and 5% per year for Medicare patients (cost ratio 1.05; 95% CI 1.03–1.07; P , 0.001). 
Costs for outpatient and emergency department visits increased significantly over time in both 
populations. Standard admission costs increased significantly for Medicare patients (cost ratio 
1.03; 95% CI 1.00–1.05; P = 0.03), but not commercial patients, and costs for intensive care 
unit visits remained stable for both populations.
Conclusion: COPD imposed a substantial economic burden on patients and the health care 
system, with costs increasing significantly in both the Medicare and commercial populations.
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Introduction
Chronic lower respiratory diseases such as chronic obstructive pulmonary disease 
(COPD) represent a substantial portion of the burden of chronic illness in the United 
States (US). In 2008, chronic lower respiratory diseases surpassed stroke to become 
the third leading cause of death in the US,1 and the US ranked second highest in COPD 
mortality in 2007 compared with 16 industrialized countries.2 Projections suggest 
that the global ranking of COPD mortality will rise relative to other causes over the 
next 20 years.3 In a study of chronic diseases among Medicare beneficiaries in 2005, 
patients with evidence of COPD comprised a greater proportion of the population 
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than patients with cancer (breast, colorectal, prostate, and 
lung cancer combined) or chronic kidney disease.4
COPD is a progressive respiratory disease defined by 
airflow limitation.5 The working definition set forth by 
the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) states: “COPD is a preventable and treatable   disease 
with some significant extrapulmonary effects that may 
  contribute to the severity in individual patients. Its pulmonary 
component is characterized by airflow limitation that is not 
fully reversible. The airflow limitation is usually progressive 
and associated with an abnormal inflammatory response of 
the lung to noxious particles or gases.”5 In addition to these 
defining characteristics, patients also exhibit chronic dyspnea 
and bronchitis, cough, sputum production, and pathologic 
features of emphysema. Patients with moderate to severe 
COPD have periods of symptom worsening superimposed on 
overall disease progression. These exacerbations negatively 
affect patient quality of life.6,7
Aims of managing stable COPD include reducing the 
frequency and severity of exacerbations as well as controlling 
baseline symptoms.5,8,9 Maintenance medications, including 
bronchodilators, inhaled corticosteroids, combination 
medications, and oxygen therapy for severe COPD are 
primarily used at home. Hospitalization is common 
for patients experiencing a severe exacerbation.5,10,11 
Severe exacerbations might be managed in an inpatient 
or emergency department (ED) setting, but life-threatening 
exacerbations may require immediate intensive care unit 
(ICU) admission.5
The high prevalence2,3,12–14 and morbidity of COPD 
contributed to a projected US$29.5 billion in related direct 
costs in 2010 in the US.2 In an analysis of commercially 
insured patients in the US in 2006, the mean annual COPD-
related health care cost per patient was estimated to range 
from US$2003 to US$43,461 (2008 cost year), depending 
on the level of care received.15 Mean hospital costs for visits 
associated with exacerbations in 2008 were estimated to range 
up to US$44,909 for ICU admissions that required intubation; 
this value increased to US$45,607 when only Medicare 
beneficiaries were included in the analysis.16,17 In a study of 
Medicare beneficiaries in 2005, the mean annual payment 
per patient with COPD, estimated as US$21,409, exceeded 
average payments for patients with heart failure, depression, 
cancer, or diabetes.4 This study of Medicare costs covered a 
period prior to the implementation of the Part D pharmacy 
benefit, and thus does not reflect pharmacy costs.
Hospitalization is a significant aspect of the burden of 
COPD. US national survey data indicate that hospitalizations 
for COPD have increased since 1990, reaching 23.6 per 10,000 
population in 2005.18   Discharge data from US hospitals in 
2007 showed that COPD accounted for 26.1   hospitalizations 
per 10,000   population aged 45–64 years; this rate was similar 
to that reported for diabetes and pneumonia in this age group.19 
For patients aged 65–74 years, however, the hospitalization 
rate for COPD more than tripled to 92.6 per 10,000 population – 
similar to pneumonia but exceeding   diabetes in this age 
group.19 In addition, Medicare   beneficiaries with COPD 
had more inpatient stays and days than patients with cancer, 
diabetes, or heart failure in 2005.4
Hospitalization is a major cost driver in COPD man-
agement overall2,15,20 and is a primary component of 
  exacerbation costs.21 Hospital care was projected to account 
for 45% of direct COPD costs in the US in 2010, whereas 
prescription drugs comprised approximately 20%.2   Inpatient 
care accounted for approximately 80% of excess costs 
for COPD patients in a matched comparison of Medicare 
  beneficiaries with and without COPD in 2004.22 Because of 
the link between exacerbations and hospitalization, reducing 
exacerbation frequency or severity could reduce COPD-
related hospitalizations and thereby reduce costs.23,24
Disease-management initiatives have potential to reduce 
health care costs associated with COPD.25 In order to assess 
the effect of such initiatives, a benchmark is needed for 
comparison. The objectives of this study are to provide a 
baseline estimate of costs of COPD-related care for patients 
in the US, including those on Medicare Advantage plus Part 
D or with commercial insurance, and to assess cost trends 
over time.
Material and methods
Data source
Medical, pharmacy, and enrolment data from a large US 
health care claims database affiliated with OptumInsight 
(formerly Innovus) were used in this retrospective study. 
Data from commercial and Medicare Advantage populations 
were used. No identifiable protected health information was 
extracted or accessed   during the course of the study. Pursuant 
to the Health Insurance Portability and Accountability Act,26 
the use of de-identified data does not require Institutional 
Review Board approval or waiver of authorization.
Patient selection
Eligible patients had either commercial (employer-based) 
insurance or Medicare Advantage with Part D benefits. 
Patients were selected for inclusion in the study based on 
evidence of COPD-related health service utilization during 
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at least one of the calendar years of interest (2006 through 
2009). Evidence of COPD-related care was based on medical 
and pharmacy claims. Specifically, patients were included if 
they fulfilled one of three criteria during a year of interest: 
(1) ED or inpatient facility claim with COPD (International 
  Classification of Diseases, Ninth   Revision, Clinical 
Modification [ICD-9-CM] code 491, 491.0, 491.1, 491.2x, 
491.8, 491.9, 492, 492.0, 492.8, or 496) in the   primary 
  diagnosis position (for an inpatient stay, the   diagnosis code 
must have been on a hospital claim); or (2) an outpatient claim 
with a primary diagnosis of COPD and a second outpatient 
medical claim with a COPD diagnosis in any position on a 
separate service date; or (3) a physician claim with a primary 
or secondary (any position other than primary) diagnosis of 
COPD and a filled prescription for a COPD maintenance 
treatment (ie, anticholinergic, long-acting beta agonist 
[LABA], or inhaled corticosteroid/LABA combination). 
Patients were also required to be at least 40 years of age 
as of the cohort year and to be continuously enrolled in the 
health plan with both medical and pharmacy benefits for the 
calendar year of interest.
Claims dated in the years 2006 through 2009 for patients 
with commercial insurance and years 2007 through 2009 for 
patients with Medicare Advantage plus Part D were included 
in the analysis. The analysis started in 2007 for the Medicare 
population because use of the Part D benefit may have been 
inconsistent or unrepresentative in 2006, the first year it was 
implemented. Study cohorts were formed based on insurance 
type and the calendar year of service: 2006, 2007, 2008, or 
2009. Patient follow-up covered each discrete calendar year; 
ie, individual patients were not followed longitudinally from 
year to year although they may have been included in more 
than 1 year-based cohort if they fulfilled the inclusion criteria 
in more than 1 year.
Data regarding patient characteristics were collected from 
enrolment information and claims. These included age, sex, 
geographic region, and evidence of comorbidities such as 
asthma. Diagnosis of asthma (ICD-9-CM 493.xx), chronic 
bronchitis (491.xx), emphysema (492.xx), or chronic airway 
obstruction not elsewhere classified (496.xx) in any position 
during the year was noted, and comorbidity burden was 
quantified using the Quan-Charlson comorbidity score.27
Cost calculations
COPD-related costs were tabulated in each year of interest 
based on total paid amounts, including patient- and health 
plan-paid amounts. Use of actual paid costs provides a view 
of the true costs of COPD incurred by payers and patients. 
Costs for commercially insured patients include estimated 
Medicare or other payer contributions based on coordination 
of benefits information. All costs were adjusted to 2008 US 
dollars using the Consumer Price Index.28
Medical costs comprise costs for COPD-related visits, 
other related medical services (ie, from claims with COPD 
diagnosis in the primary position that did not fall into 
specified visit categories), and oxygen use. COPD-related 
visits included outpatient, urgent outpatient, and ED visits, 
as well as standard admissions (no ICU) and ICU stays. An 
“outpatient” visit was defined as a medical claim for office 
or outpatient care with COPD indicated in the primary or 
secondary position, but no evidence of an “urgent” visit 
(defined below). Outpatient care included physician office 
visits, outpatient hospital services, laboratory visits, and 
urgent care center visits. An “urgent outpatient” visit was 
based on a medical claim for outpatient care for COPD 
(primary or secondary position) followed by a pharmacy 
claim for an oral corticosteroid or antibiotic within 7 days 
after the visit. An “ED” visit was based on a medical claim 
for an ED visit for COPD (primary position). A “standard 
admission” was based on an inpatient stay for COPD (diag-
nosis in the primary position on a hospital claim), but no 
evidence of ICU treatment during the stay. “ICU” care was 
defined as a medical claim during an inpatient stay with 
revenue code of 020x, 021x, 0223, or 0234 or a current 
procedural terminology (CPT) procedure code for critical 
care (99291–99292). Oxygen use was identified by medi-
cal procedure (CPT/HCPCS E0424–E0444, E0445, E0455, 
E0550, E0560, E1353–E1372, E1399, K0740; ICD-9 
93.96), diagnosis (ICD-9 V46.2), and facility revenue codes 
(0277, 0544, 060x).
COPD-related pharmacy costs were summed from 
pharmacy claims for any of the following medications: 
short-acting beta agonists, LABAs, anticholinergics, 
methylxanthines, oral/intravenous corticosteroids, inhaled 
corticosteroids, inhaled corticosteroid/LABA combinations, 
other respiratory medications, or antibiotics.
Patient- and visit-level analyses
Patient-level costs were calculated as the sum of costs during 
the year of interest and reported as the mean annual cost among 
patients in the year-based cohort. COPD-related medical and 
pharmacy costs are reported separately in the patient-level 
analysis, and total COPD-related health care costs are the sum 
of COPD-related medical and pharmacy costs. Visit-level costs 
were calculated based on all visits of a given type during the 
year and are reported as the mean cost per COPD-related care 
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episode. Multivariate models were used to assess patient-level 
and visit-level cost trends over time.
COPD-related hospital readmissions were also assessed. 
COPD-related readmissions were defined as COPD-related 
hospital stays (primary diagnosis of COPD) that occurred 
after the initial COPD-  related admission (ie, patients who 
had more than one COPD-related hospital stay in the study 
year were considered to have a readmission). The percentages 
of patients with readmissions within 30 days and 60 days of 
the initial admission are also reported. ED visits were not 
considered in the assessment of readmissions.
Statistical analysis
Patient- and visit-level costs are reported with descriptive 
  statistics. Trends over time were investigated with generalized 
linear models with gamma distribution and log link to account 
for the skewed distribution of costs.29 The models adjusted 
for sex, age category, and geographic region, with year as the 
primary predictor. The models did not adjust for comorbidity 
because changes in costs for COPD care year over year might 
be related to management of associated comorbid conditions. 
The authors did not want to “control away” differences in 
comorbid status that are clinically associated with COPD. A 
threshold of P , 0.05 was used to define statistical signifi-
cance. The multivariate models were fit by Stata 10.0 (Stata-
Corp, College Station, TX) software, and all other analyses 
were conducted using SAS® 9.1 (SAS Institute, Cary, NC).
Results
Patient characteristics
Demographics and comorbidities of the commercial and 
Medicare Advantage COPD patient cohorts in 2009 are 
shown in Table 1. Characteristics of the patient cohorts 
from years 2006 through 2008 are shown in Appendix 1. 
Across each year studied, demographic characteristics 
of commercial cohorts were similar to each other and 
characteristics of Medicare Advantage cohorts were simi-
lar to each other. The highest proportion of patients was 
from the South region for all commercial and Medicare 
  Advantage cohorts, which reflects the distribution of 
patients in the overall database population. In each year 
studied, the mean age of the   Medicare Advantage cohort 
was approximately 10 years older than that of the com-
mercial cohort, as expected.
Within each year, the proportions of patients with the 
respiratory comorbidities noted in Table 1 were similar 
between the commercial and Medicare Advantage samples. 
Patients in the Medicare cohort had more comorbidities than 
the commercial cohort as evidenced by higher mean Quan-
Charlson comorbidity index score. This relationship held true 
over time. Approximately 30% of patients in the commercial 
and Medicare Advantage cohorts in each year had evidence 
of comorbid asthma.
Patient-level costs of COPD
Mean annual COPD-related health care costs for each 
  commercial insurance and Medicare Advantage cohort are 
shown in Figure 1. Medical costs, which comprise amounts 
paid for facility and physician services, accounted for the 
majority of total costs in all cohorts. COPD-related medical 
costs were approximately 16%–19% lower for Medicare 
than commercial cohorts, and total costs were approximately 
7%–10% lower for Medicare than commercial cohorts in each 
year that both insurance types were studied.
Based on the multivariate analysis, total costs increased 
over time for both Medicare Advantage and commercial 
insurance patients after adjustment for age, sex, and region. 
The rate of increase for total costs was approximately 6% per 
year for commercial insurance patients and 5% per year for 
Medicare Advantage patients (Table 2). Both pharmacy 
and medical costs increased significantly over time for the 
commercial population, but only medical costs increased 
significantly for the Medicare Advantage population (Table 2). 
Table  1  Characteristics  of  patients  with  chronic  obstructive 
pulmonary disease and commercial insurance or Medicare
2009
Commercial 
(N = 51,210)
Medicare 
(N = 42,166)
n % n %
Male 24,597 48.0 18,503 43.9
Region
  Northeast 5168 10.1 5262 12.5
  Midwest 11,972 23.4 14,880 35.3
  South 27,345 53.4 18,499 43.9
  West 6725 13.1 3525 8.4
Age group
  40–49 5581 10.9 717 1.7
  50–64 26,933 52.6 5493 13.0
  65–74 9919 19.4 17,605 41.8
 $ 75 8777 17.1 18,351 43.5
Age; mean, SD 62.7 11.1 72.7 9.2
Comorbidities
  Asthma 16,148 31.5 12,318 29.2
  Chronic bronchitis 22,365 43.7 19,324 45.8
  Emphysema 9711 19.0 9343 22.2
  Chronic airway obstructiona 43,045 84.1 38,821 92.1
Quan-Charlson index; mean, SD 2.5 1.9 3.3 2.3
Note: aNot elsewhere specified. 
Abbreviation: SD, standard deviation.
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Pharmacy costs accounted for a small proportion of total 
COPD costs for both cohorts.
For Medicare Advantage patients, mean (and standard 
deviation) cost associated with oxygen use increased from 
US$758 (US$3595) in 2007 to US$871 (US$3095) in 
2009. Over the same time period, mean cost associated with 
oxygen use increased from US$459 (US$2155) to US$501 
(US$2897) for patients with commercial insurance.
Visit-level costs of COPD
Mean costs of nonhospital COPD-related visits by year 
and insurance type are shown in Figure 2, and costs of 
standard admissions and ICU visits are shown in Figure 3. 
  Commercially insured patients accounted for greater costs 
than Medicare Advantage patients for ambulatory visits, 
standard admissions, and ICU care, whereas Medicare 
patients accounted for greater ED costs than commercial 
patients. Cost values are shown in Appendix 2.
After adjustment for age, sex, and region; costs for 
outpatient, urgent outpatient, and ED visits increased 
significantly over time in both populations (Table 2). The 
rate of increase for outpatient visit costs was approximately 
6% per year for commercial patients, but only 2% per 
year for Medicare Advantage patients (Table 2). Costs for 
standard admissions increased significantly over time for 
patients with Medicare, but not for those with commercial 
insurance, and costs for ICU care remained stable for both 
populations.
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Note: Costs are adjusted to year 2008 and are in USD.
Table  2  Adjusted  chronic  obstructive  pulmonary  disease-related  subject-level  and  visit-level  cost  ratios  with  year  as  primary 
predictor
Commercial 2006–2009 P Medicare 2007–2009 P
Cost ratio 95% CI Cost ratio 95% CI
Subject level
  Medical 1.06 1.04–1.09 , 0.0001 1.07 1.05–1.10 ,0.001
  Pharmacy 1.05 1.04–1.05 , 0.0001 0.99 0.98–1.00 0.17
  Total 1.06 1.04–1.07 , 0.0001 1.05 1.03–1.07 ,0.001
Visit level
  Outpatient 1.06 1.04–1.07 , 0.0001 1.02 1.00–1.04 0.05
  Urgent outpatient 1.07 1.05–1.10 , 0.0001 1.09 1.04–1.14 0.001
  Emergency department 1.04 1.02–1.06    0.001 1.06 1.03–1.09 ,0.001
  Standard admission 1.01 0.98–1.03    0.59 1.03 1.00–1.05 0.03
  Intensive care unit 1.02 0.97–1.08    0.38 1.00 0.93–1.08 0.97
Notes: Generalized linear models adjusted for age, sex, and region. Total costs increased by approximately 6% per year for commercial insurance patients and 5% per year 
for Medicare patients.
Abbreviation: CI, confidence interval.
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COPD readmissions
Among patients with a standard admission or ICU stay 
(eg, in 2009, 7.5% [3852/51,210] of commercially insured 
patients and 10.7% [4511/42,166] of Medicare Advantage 
patients had at least one inpatient visit), the proportion with a 
readmission during the study year ranged from 13%–14% for 
the commercial population and 16%–19% for the Medicare 
Advantage population, depending on the year (2006–2009). 
Of all readmit visits among commercially insured patients, 
approximately 31%–34% (depending on the year) occurred 
within 30 days of the initial admission and 47%–49% 
occurred within 60 days (the number of readmit visits within 
60 days includes the number that occurred within 30 days 
of the initial admission). Similarly, 30%–32% (depending 
on the year) of readmit visits among Medicare Advantage 
patients occurred within 30 days of the initial admission, 
and 49%–52% occurred within 60 days.
Discussion
Annual per-patient COPD-related total direct health care 
costs increased over time: by approximately 6% per year 
for commercially insured patients from 2006 through 2009 
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and 5% per year for Medicare Advantage patients from 2007 
through 2009, after adjustment. Medical costs accounted for 
the majority of patient-level costs among both commercially 
insured patients and those with Medicare. Costs per inpatient 
care episode were substantial and relatively stable, except 
for an increase in standard admission costs for Medicare 
Advantage patients.
Hospital-perspective data from 2005 through 2008 
produced similar visit-level results.16 Relative to 2005, 
hospital costs for a standard admission were 6%–11% 
higher and ED costs were 4%–10% higher over the period 
2006 through 2008, but a consistent upward trend was 
not evident.16 Hospital costs for encounters with ICU or 
intubation varied by less than 3% from 2005 through 2008,16 
which is consistent with the findings of this present study 
that total payer- and patient-paid ICU costs did not increase 
significantly over the studied period. Notwithstanding this 
lack of increase, ICU stays were expensive for both the 
commercial and Medicare Advantage populations. ICU 
visit costs for commercially insured patients were more 
than double the costs for patients on Medicare Advantage. 
Possible reasons for this discrepancy include Medicare cost 
control and the difference in age between the populations. 
The commercial patients were younger on average, and it 
is possible that younger patients receive more aggressive 
or costly care independent of insurance type. However, 
this study did not address these possible explanations and 
additional research is needed.
It would be of interest to compare costs between   Medicare 
and commercial enrollees aged 65 and older, but cost 
differences are difficult to parse out due to differences in the 
populations as well as because of how costs are calculated. 
The age 65 and older commercial population consists of 
patients still working, retirees, and patients with spouses 
who retain commercial insurance. Because commercial 
benefits are coordinated with Medicare, costs (primarily 
for hospitalization services, but in some cases for Part B 
services) are necessarily calculated using an estimator of the 
contribution of Medicare to paid amounts. Addressing this 
complex issue was beyond the scope of the study.
The data provide a benchmark for assessing the impact 
of changes in COPD management practices. Because 
ICU stays and hospitalizations for patients with COPD 
can often be the result of exacerbations, reducing the 
frequency of severe exacerbations could help to control 
COPD-related costs. Treatments that reduce the frequency 
of COPD-related hospitalizations or exacerbations11 are 
also associated with lower COPD-related medical costs, 
and in some cases lower total COPD-related costs.30,31 
Additional research is needed to investigate the interrela-
tionships among treatment for COPD, risk of exacerbation 
and hospitalization, and costs.
Like previous studies, patients in this present analysis had 
a high rate of readmissions, and many of these visits occurred 
within a month of the index visit. An analysis of Medicare 
claims from 2003 through 2004 reported a readmission rate 
of 23% for patients with an initial admission for COPD.32 
Patients with an initial COPD-related admission accounted 
for 4% of all rehospitalizations observed in that study, and 
COPD was the third most common index condition associated 
with rehospitalization, after heart failure and pneumonia.32 
Records from five New York City hospitals indicate that 22% 
of hospitalizations for COPD exacerbations in a 2-year period 
are repeat admissions; 17.6% of patients are readmitted at 
least once.33 Hospital data from 2008 indicate that between 
15% and 18% of patients with an initial ED or inpatient 
visit for COPD have a repeat visit within 60 days.16,17 Given 
the high rate of hospitalization of patients with COPD, 
interventions aimed at reducing the need for COPD-related 
admissions and readmissions may help to lessen resource 
use and costs for this patient population.
Like all retrospective claims-based studies, this study 
is limited by constraints of the data source, and results 
must be interpreted in the context of these limitations. 
Claims are collected for payment, not research, and 
  coding errors are possible. Although this present analysis 
included only direct costs, indirect costs of COPD are 
also substantial,2,23,34 and the results of this present study 
are likely to underestimate the overall burden of COPD. 
Clinical measures of COPD severity were not available in 
the dataset, and thus the influence of severity on annual or 
visit costs could not be determined. The results might not 
generalize to uninsured patients or patients in areas with 
limited access to medical care. Finally, each calendar year-
based cohort was identified separately – patients were not 
examined longitudinally – and there is overlap between 
cohorts from year to year.
Conclusion
The economic burden of COPD on patients and payers 
grew from 2006 through 2009, and much of these costs are 
attributable to medical expenses. This information can be 
used to evaluate the effect of changes in the practice of COPD 
management. Improved symptom management could reduce 
demand for high-cost medical resources, such as ICU care, 
and reduce overall COPD-related costs.
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Appendix tables
Appendix 1 Characteristics of patients with chronic obstructive pulmonary disease by insurance type
2006 2007 2008
Commercial 
(N = 47,147)
Commercial 
(N = 49,661)
Medicare 
(N = 24,222)
Commercial 
(N = 52,056)
Medicare 
(N = 30,183)
n % n % n % n % n %
Male 23,014 48.8 24,080 48.5 10,783 44.5 25,126 48.3 13,308 44.1
Region
  Northeast 5240 11.1 5496 11.1 2638 10.9 5541 10.6 3505 11.6
  Midwest 12,966 27.5 12,412 25.0 10,705 44.2 12,760 24.5 11,579 38.4
  South 21,970 46.6 25,250 50.8 10,109 41.7 26,861 51.6 13,501 44.7
  West 6971 14.8 6503 13.1 770 3.2 6894 13.2 1598 5.3
Age group
  40–49 6269 13.3 5972 12.0 360 1.5 5776 11.1 466 1.5
  50–64 24,864 52.7 25,789 51.9 2648 10.9 26,851 51.6 3703 12.3
  65–74 8670 18.4 9619 19.4 9767 40.3 10,454 20.1 12,089 40.1
 $ 75 7344 15.6 8281 16.7 11,447 47.3 8975 17.2 13,925 46.1
Age; mean, SD 61.8 11.0 62.4 11.1 73.4 8.7 62.7 11.1 73.1 9.0
Comorbidities
  Asthma 15,355 32.6 15,905 32.0 6572 27.1 16,714 32.1 8423 27.9
  Chronic bronchitis 20,068 42.6 20,942 42.2 10,225 42.2 22,929 44.0 13,907 46.1
  Emphysema 9494 20.1 9861 19.9 5444 22.5 10,045 19.3 6863 22.7
  Chronic airway obstructiona 38,904 82.5 41,537 83.6 22,260 91.9 43,441 83.5 27,746 91.9
Quan-Charlson index; mean, SD 2.3 1.8 2.4 1.9 3.2 2.2 2.4 1.9 3.3 2.3
Note: aNot elsewhere specified. 
Abbreviation: SD, standard deviation.
Appendix 2 Unadjusted visit-level costs of chronic obstructive pulmonary disease-related visits in 2006 through 2009 for patients with 
commercial insurance or Medicare Advantage
Visit type Year Commercial Medicare
Mean SD 25th  
percentile
Median 75th  
percentile
Mean SD 25th  
percentile
Median 75th  
percentile
Outpatient 2006 306 1366 54 89 171 – – – – –
2007 313 1284 55 90 175 178 614 59 87 122
2008 332 1475 56 93 180 183 667 58 86 121
2009 363 1638 58 95 185 186 628 58 86 120
Urgent  
outpatient
2006 277 1208 57 92 158 – – – – –
2007 279 1253 57 91 157 230 1050 60 89 124
2008 309 1364 59 94 165 248 1159 59 87 122
2009 340 1572 61 97 168 266 1244 61 87 123
Emergency  
department
2006 315 460 109 226 394 – – – – –
2007 302 388 115 233 389 375 451 89 265 488
2008 332 348 156 274 428 409 463 126 296 532
2009 345 331 158 290 454 429 504 157 309 567
Standard  
admission
2006 9799 13,644 3078 6246 10,492 – – – – –
2007 10,579 19,850 2906 6337 10,890 6968 6283 4907 5677 6910
2008 9936 12,783 3206 6913 11,522 7353 7289 4707 5856 7518
2009 10,170 12,755 3598 6958 11,453 7430 6098 4593 6059 8122
Intensive  
care unit
2006 35,583 73,705 6308 12,061 34,114 – – – – –
2007 38,438 91,401 6613 13,854 33,135 14,085 31,018 5517 6573 12,289
2008 38,198 81,996 7198 14,367 32,669 14,532 20,966 5714 7407 13,880
2009 39,229 78,548 7927 14,560 35,979 14,112 22,885 5553 7824 12,650
Note: All values are USD. 
Abbreviation: SD, standard deviation.
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